Efficacy and Safety of the New Intravenous Immunoglobulin IGIV 10% in Adults with Chronic Idiopathic Thrombocytopenic Purpura

Gyula Varga\textsuperscript{a} Zuzana Volková\textsuperscript{b} H. Leibl\textsuperscript{c} Zoltán Gasztonyi\textsuperscript{d} Antonín Hlusi\textsuperscript{e} Jiri Mayer\textsuperscript{f} Krzysztof Chojnowski\textsuperscript{g} Hans-Heinrich Wolf\textsuperscript{h} Marlies Sharkhawy\textsuperscript{c} Borislava G. Pavlova\textsuperscript{c} Karl Birthistle\textsuperscript{c} Werner Engl\textsuperscript{c} Simone Walter\textsuperscript{c} Hartmut J. Ehrlich\textsuperscript{c}, and the ITP-IGIV 10% Study Group\textsuperscript{a}

\textsuperscript{a}University of Szeged, Szeged, Hungary
\textsuperscript{b}Institute of Haematology & Blood Transfusion, Prague, Czech Republic
\textsuperscript{c}Baxter, Vienna, Austria
\textsuperscript{d}Petz Aladár Teaching Hospital, Győr, Hungary
\textsuperscript{e}University Hospital, Olomouc, Czech Republic
\textsuperscript{f}University Hospital, Brno, Czech Republic
\textsuperscript{g}Medical University of Lodz, Lodz, Poland
\textsuperscript{h}Martin-Luther-Universität, Halle, Germany

Summary

Background: Intravenous immunoglobulin (IGIV) 10% is a newly developed 10% liquid immunoglobulin preparation for intravenous use where 3 dedicated

10% liquid reduction steps have been integrated into the manufacturing process. The efficacy and safety of this product were assessed in a prospective multicenter study in chronic ITP (idiopathic thrombocytopenic purpura) patients with platelet counts of \( \leq 20 \times 10^9/l \). Patients and Methods: 23 adult ITP patients received the product at a total dose of 2 g/kg body weight adminis-

tered over 2–5 days, and were followed for 4 weeks.

Results: Of the 21 subjects included in the Per-Protocol Analysis Data Set, 15 responded successful-

ly to treatment (71.4%). Eleven subjects in this group attained a platelet count \( \geq 50 \times 10^9/l \) by day 8, and 14 of them reached this level by day 5. The median duration of platelet response was 25 days, and the highest median platelet count in the responders was \( 182 \times 10^9/l \). A total of 81 infusions were administered to the 23 subjects in the Safety Analysis Data Set over the course of the study. There were 40 non-serious adverse events related to the use of the study drug – 35 mild, 3 moderate, and 2 severe. The most frequent related adverse events were headache and pyrexia. Conclusion: The results obtained in this study demonstrate that IGIV 10% is effective in the treatment of adult subjects with chronic ITP and indicate a good safety profile.

Schlüsselwörter

IGIV · Intravenöses Immunglobulin · Idiopathische thrombozytopenische Purpura · Chronische ITP

Zusammenfassung

Hintergrund: Intravenöses Immunglobulin (IGIV) 10% ist ein neu entwickeltes 10%iges flüssiges Immunglobulinpräparat zur intravenösen Administration, bei dessen Herstellung 3 spezifische Schritte zur Viruskontrolle/-eliminie-

rung zur Anwendung kommen. Die Wirksamkeit und Sicherheit dieses Präpa-

rats wurden in einer prospektiven, multizentrischen Studie in Patienten mit chronischer (ichtopathischer thrombozytopenischer Purpura (ITP) manifestiert

durch eine Thrombozytenzahl von \( \leq 20 \times 10^9/l \) nachgewiesen. Patienten und Methoden: 23 erwachsenen ITP-Patienten wurde eine Gesamtdosis von je 2 g IGIV 10% pro kg Körpergewicht über 2–5 Tage verteilt verabreicht. Der nach-

folgende Beobachtungszeitraum erstreckte sich über 4 Wochen. Ergebnisse: Von den 21 Patienten, die die Kriterien laut Studienplan erfüllten, sprachen 15 (71,4\%) auf die Behandlung an. In 11 Patienten stiegen die Thrombozyten auf

über 100 \( \times 10^9/l \), in 8 konnte ein Anstieg auf über 200 \( \times 10^9/l \) beobachtet wer-

den. Alle 15 Responder hatten einen Anstieg auf mindestens 50 \( \times 10^9/l \) bis zum Tag 8 nach Behandlungsbeginn, 14 davon bereits bis zum Tag 5. Der Me-

dian der Dauer des Responses auf die Produktgabe betrug 25 Tage, und der Median der maximalen in Respondern gemessenen Werte lag bei 182 \( x 10^9/l \). Die 23 Studienteilnehmer, die alle in die Auswertung der Produktreaktion einbezogen wurden, erhielten im Rahmen der Studie insgesamt 81 Infusion-

nen. Von 40 berichteten nicht schwerwiegenden Nebenwirkungen wurden 35 als leicht, 3 als mäßig schwer und 2 als schwer klassifiziert. Die häufigsten dieser produktbedingten unerwünschten Ereignisse waren Kopfschmerz und Pyrexie. Schlussfolgerung: Die Ergebnisse der Studie zeigen die Wirksamkeit

von IGIV 10% in der Behandlung Erwachsener mit chronischer ITP und das gute Sicherheitsprofil des Produkts.
Introduction

Many patients and clinicians rely on therapeutic proteins, such as intravenous immunoglobulin (IGIV), isolated from human blood plasma. Even though the pathogen safety records for IGIV and other plasma proteins are excellent, ascertaining and ensuring pathogen safety of plasma-derived therapeutics continues to be a priority among manufacturers and health authorities [1–3]. From a pharmaco-economic point of view, the continued efforts to maintain and improve blood safety may go well beyond accepted norms of cost-effectiveness in medical interventions [4–6]. However, this approach has been singularly effective in managing agents traditionally considered to pose the highest risk to the patient [4]. As plasma remains predisposed to contamination by a variety of blood-borne pathogens including new or re-emerging infectious agents [1–3, 7], transfusion specialists and regulatory agencies are now focusing a similar degree of attention on emerging infections with a view to balancing the need for both the safety of the blood supply and the availability of lifesaving blood and blood products [3, 4].

The new 10% liquid immunoglobulin preparation, IGIV 10% (KIOVIG™, Baxter International Inc., Deerfield, IL, USA), was developed to provide a preparation with an increased margin of safety. Furthermore, formulation as a 10% liquid preparation offers the advantage of easier use by physicians, pharmacists, nurses and patients, and allows for smaller volumes of product to be infused (compared to 5% formulations). In the past, various state-of-the-art methods for virus reduction were developed and described in publications [51x415]. In the past, various state-of-the-art methods for virus reduction were developed and described in publications [51x428]. In the past, various state-of-the-art methods for virus reduction were developed and described in publications [51x440]. In the past, various state-of-the-art methods for virus reduction were developed and described in publications [51x453]. In the past, various state-of-the-art methods for virus reduction were developed and described in publications [51x465]. In the past, various state-of-the-art methods for virus reduction were developed and described in publications [51x478]. In the past, various state-of-the-art methods for virus reduction were developed and described in publications [51x490]. In the past, various state-of-the-art methods for virus reduction were developed and described in publications [51x503]. In the past, various state-of-the-art methods for virus reduction were developed and described in publications [51x516]. In the past, various state-of-the-art methods for virus reduction were developed and described in publications [51x541]. In the past, various state-of-the-art methods for virus reduction were developed and described in publications [51x554]. In the past, various state-of-the-art methods for virus reduction were developed and described in publications [51x579]. In the past, various state-of-the-art methods for virus reduction were developed and described in publications [51x591]. In the past, various state-of-the-art methods for virus reduction were developed and described in publications [51x604]. In the past, various state-of-the-art methods for virus reduction were developed and described in publications [51x629]. In the past, various state-of-the-art methods for virus reduction were developed and described in publications [51x641]. In the past, various state-of-the-art methods for virus reduction were developed and described in publications [51x654]. In the past, various state-of-the-art methods for virus reduction were developed and described in publications [51x666]. In the past, various state-of-the-art methods for virus reduction were developed and described in publications [51x691]. In the past, various state-of-the-art methods for virus reduction were developed and described in publications [51x704]. In the past, various state-of-the-art methods for virus reduction were developed and described in publications [51x716]. In the past, various state-of-the-art methods for virus reduction were developed and described in publications [51x741].

The study drug was a prospective, open-label, non-controlled, multicenter study. Subjects eligible for treatment received a total dose of 2 g/kg body weight (total dose 2 g/kg) were administered [26, 30–33]. However, other treatment regimens (1,000 mg/kg over 2 days) have also been described and reported to be successful in individual patients [27]. The efficacy and safety of high-dose treatment of adult chronic ITP patients with IVIG 10% were assessed in a prospective, multicenter study.

Patients and Methods

Study Drug

IGIV 10% is a ready-to-use liquid IGIV at 10% w/v protein concentration with a pH of 4.6–5.1, allowing for smaller volumes of product to be infused compared to traditional 5% products. The stabilizing agent is 0.25 mol/l glycine. The product contains no preservatives and no glucose or sucrose. The manufacturing process of IGIV 10% is based on frozen human plasma and includes a modified Cohn-Onceley cold alcohol fractionation procedure and ion exchange chromatography steps. 3 dedicated virus reduction steps are included in the manufacturing process: i) incubation for ≥60 min at 18–25 °C with a solvent-detergent mixture of 0.3% tri-n-butyl phosphate, 1.0% Triton X-100, and 0.3% Tween 80 to inactivate lipid-enclosed viruses; ii) nano-filtration through 35 nm filters to remove enveloped and non-enclosed viruses and other pathogens by size exclusion; and iii) incubation of final container vials for 21–22 days at 30–32 °C and a pH of 4.6–5.1 to neutralize enveloped and non-encapsulated viruses.

Subjects

Adult subjects were eligible for enrolment in the study if they were diagnosed with ITP at least 6 months prior to study entry, and had a baseline platelet count of ≤20 × 109/l determined prior to administration of the study drug on the day of the first infusion. They should have had no IGIV treatment for ITP during the 2 weeks prior to the first infusion of the study drug. Exclusion criteria included but were not limited to: increased serum values of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, and/or total bilirubin, renal dysfunction, other underlying autoimmune or lymphoproliferative disorder, cardiac insufficiency, treatment with another investigational drug in the 4 weeks prior to study entry and history of severe adverse reactions to blood and/or blood products.

Eleven study sites in Germany, the Czech Republic, Hungary and Poland administered IGIV 10% to a total of 23 adult subjects with chronic ITP. Two of the subjects did not meet all selection criteria (one had a platelet count of >20 × 109/l, the other was diagnosed with ITP less than 6 months prior to study entry). Therefore, efficacy results were calculated separately for the subjects who received IGIV 10% and were monitored for platelet count (Full Analysis Data Set, FADS, n = 23) and for the subjects who met all selection criteria, received IGIV 10% and were monitored for platelet count (Per-Protocol Analysis Data Set, PADS, n = 21). The Safety Analysis Data Set (SADS) comprised all subjects who received IGIV 10% and was identical to the FADS (n = 23).

Study Design

The study was a prospective, open-label, non-controlled, multicenter study. Subjects eligible for treatment received a total dose of 2 g/kg IGIV 10% administered over 2–5 days. A maximum of 2 booster doses, each ranging from 400 to 1,000 mg/kg, were permitted if the platelet count remained at one third to one half the normal value of 150–350 × 109/l but can also drop to very low levels. Chronic ITP rarely relapses spontaneously. Treatments for ITP generally include corticosteroids, other immunosuppressive agents, anti-D immunoglobulin, IGIV and splenectomy [21, 25]. Since the initial report by Imbach et al. [26], several studies have confirmed the efficacy of high-dose treatment with IGIV infusions in patients with ITP [27]. The platelet count rises rapidly after immunoglobulin treatment, and sustained platelet response has been observed in some patients [28, 29]. Various regimens have since been proposed for immunoglobulin treatment of patients with ITP. Originally, 5 daily doses of
All other subjects were followed until day 29. Platelet counts were determined at screening and on days 1 (initiation of treatment course), 2, 5, 8, 11, 15, 22, and 29. Blood samples for platelet determination on treatment days were drawn prior to study drug administration. Subjects already receiving corticosteroids at entry into the study could be continued on corticosteroid treatment in doses equivalent to 20 mg or less of prednisone daily during the treatment and follow-up periods in the study. However, the dose had to be steady or decreasing during the study period.

The study was conducted in accordance with the principles of the Declaration of Helsinki (Somerset West 1996), the Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95) and valid national laws. The clinical protocol was approved by the respective ethics committees and, after having been informed of the aspects of study participation, informed consent forms were signed by the study subjects.

**Evaluation of Efficacy and Safety**

The primary endpoint of the study was the number of treatment responders. A responder was defined as a subject who i) had a platelet increase to ≥20 x 10^9/l at least once prior to day 15 and ii) did not require a booster dose prior to day 15. Secondary endpoints were the time taken to achieve a platelet count of ≥20 x 10^9/l, the duration of platelet response, the maximum platelet count, and regression of hemorrhages.

For evaluation of safety, all AEs occurring between the baseline visit and the end of the study were recorded. A Coombs' test was performed before the first infusion and on day 8.

**Statistical Analysis**

The proportion of platelet count responders and a two-sided 95% confidence interval (CI) for the proportion was given using the Wilson score method without continuity correction [34]. The median and 95% CI for the time taken to achieve predefined platelet response were estimated from the beginning of the first infusion until the first measurement of a platelet count of ≥50 x 10^9/l by the Kaplan-Meier technique. The duration of platelet response was defined as the number of days from the day the platelet count reached or exceeded 50 x 10^9/l to either the first day the platelet count fell to <20 x 10^9/l or the last day with available platelet count data, whichever occurred first. The median and a two-sided 95% non-parametric CI for the duration of platelet response were calculated. Medians, quartiles and their non-parametric two-sided 95% CI were used to describe the maximum platelet count which was defined as the highest platelet count achieved on or after day 5.

The median time to complete cessation of any hemorrhage was estimated by the Kaplan-Meier method (and included the two-sided 90% CI for the median). This analysis was performed for the subset of subjects who presented with hemorrhages on day 1. The time period for the regression of hemorrhages was expressed in integer days. The day when the regression of hemorrhage occurred was defined as the first day when all the subject's bleeding-related AEs had stopped and no new bleeding was reported to have started on that day.

**Results**

23 subjects were enrolled and treated (SADS). All 23 subjects were white Europeans, 13 were male, 10 were female. Age ranged between 18 and 68 years with a median of 49 years, body weight ranged from 58 to 116 kg with a median of 80 kg. The most frequent disorders besides ITP and related disorders reported in the medical history (SADS) were cardiovascular disorders (10 subjects). 9 subjects had a history of hypertension. In 7 of these, mild or moderate hypertension was determined at enrolment. 9 subjects in the SADS had previously had a splenectomy, and 9 subjects had been receiving systemic corticosteroids in doses equivalent to 20 mg or less of prednisone daily in the 2 weeks preceding the first treatment. 8 subjects continued steroid treatment at steady or decreasing doses during the treatment and follow-up period. 2 of the 23 subjects did not meet all selection criteria and were excluded from the PADS (n = 21).

**Efficacy**

15 of the 21 subjects (71.4%, 95% CI for proportion 50.0–86.2%) in the PADS responded to treatment, while the number of treatment responders was 17 of 23 subjects (73.9%, 95% CI for proportion 53.5–87.5%) in the FADS. Box plots of platelet counts for the treatment responders of the PADS throughout the study are displayed in figure 1. The median platelet count in both the PADS and the FADS (including treatment responders and non-responders) was ≥50 x 10^9/l by study day 5 (median 85 x 10^9/l, in the 2 analysis data sets). Eleven subjects in the PADS presented with an increase to >100 x 10^9/l, and 8 subjects also reached a platelet count of >200 x 10^9/l over the course of the study. In the FADS, 12 subjects achieved a platelet count of >100 x 10^9/l, and 9 reached >200 x 10^9/l. The highest median platelet count among treatment responders in the PADS and the FADS was 182 x 10^9/l (range 17–435 x 10^9/l), observed on day 8. The median platelet count on day 5 in treatment responders in either analysis data set was 163 x 10^9/l (range 42–271 x 10^9/l). All of the treatment responders in the PADS and the FADS achieved a platelet count of ≥50 x 10^9/l by day 8 (within 7 days of initiation of treatment). 14 treatment responders in the PADS (93.3%) and 15 in the FADS (88.2%) achieved this platelet count as early as day 5 (i.e. within 4 days of treatment initiation). The median duration of platelet response was 25
days for the treatment responders in both the PADS and the FADS (95% CI 21–28 and 22–28, respectively).

Five subjects in the PADS and 6 in the FADS presented with a hemorrhage on day 1, i.e. the day of the onset of the initial study drug treatment course. The median time to regression of the hemorrhage was 4 days (90% CI 0–4 days) in the PADS and 2 days (90% CI 0–4 days) in the FADS.

Of the 6 non-responders to study drug treatment observed in the current study, 5 received a booster dose in the 2 weeks after initiation of the first infusion. With one exception, none of these subjects achieved a platelet count of $\geq 50 \times 10^9/l$ after receiving a booster dose. In the subject that did achieve a platelet count of $\geq 50 \times 10^9/l$ the increase was most likely due to concomitant therapies for ITP initiated by the investigator when the platelet count remained low after IGIV administration.

**Safety and Tolerability**

A total of 81 infusions of IGIV 10% (initial treatment course and booster) were administered during the study. The total dose of 2 g of IGIV 10%/kg was to be given within a treatment course of 2–5 consecutive days. The majority of the subjects treated (SADS) received the total dose in 2 days (12 of 23). Distribution of treatment courses and amount of product administered are shown in table 1. The duration of individual infusions of the initial treatment course ranged from 2.0 to 6.1 h (median 4.0 h), the minimum initial infusion rate was 0.35 ml/kg/h, the highest maximum infusion rate was 8 ml/kg/h. Details of infusion rates are shown in table 2.

A total of 84 AEs were reported in 18 subjects. Only 1 serious adverse event (SAE) was reported. This was a prolongation of hospitalization due to the observation of a hematoma in the right thigh and petechiae in a subject who was non-responsive to study drug treatment. The SAE was considered by the investigator to be unrelated to the use of the study drug. The majority (68 of 83, i.e. 81.9%) of the non-serious AEs reported were mild, 11 (13.3%) were moderate, and 4 (4.8%) were severe. 40 of the reported non-serious AEs were considered by the investigators to be related to the use of the study drug. Of these, 35 (87.5%) were mild, 3 (7.5%) were moderate, and 2 (5.0%) were severe. The most frequently reported related AE was headache followed by pyrexia (table 3). 6 of 23 subjects (26.1%) experienced hemorrhages which began after the first infusion of the study drug. Bleedings reported included: contusion (1 subject, 4.3%), epistaxis (3 subjects, 13.0%), gingival bleeding (2 subjects, 8.7%), hematoma (2 subjects, 8.7%), non-specific hemorrhage (3 subjects, 13.0%) and petechiae (3 subjects, 13.0%). Several subjects had more than one type of bleeding. All 23 subjects analyzed (SADS) tested negative in the direct Coombs’ tests at baseline. In the follow-up tests, 3 subjects (13.0%) tested positive in the direct Coombs’ test. No AEs involving hemolysis were reported during the study and no evidence of drug-induced hemolysis for these cases was found.

**Table 1. Summary of dose administered – SADS**

<table>
<thead>
<tr>
<th>Parameter / Statistic</th>
<th>Infusions, n</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects, n</td>
<td>12 4 2 5 23</td>
<td></td>
</tr>
<tr>
<td>Total dose infused, g</td>
<td>152 192 204 162 166</td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>28 42 40 23 34</td>
<td></td>
</tr>
<tr>
<td>Total dose per kg infused, g/kg</td>
<td>1.99 2.00 2.01 2.00 2.00</td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>0.04 0.01 0.04 0.03</td>
<td></td>
</tr>
<tr>
<td>Total volume infused, ml</td>
<td>1.533 1.938 2.050 1.650 1.674</td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>281 399 424 235 340</td>
<td></td>
</tr>
</tbody>
</table>

**Table 2. Summary of infusion rates (initial treatment course)**

<table>
<thead>
<tr>
<th>Statistic</th>
<th>Duration of infusion, h</th>
<th>Initial infusion rate, ml/kg/h</th>
<th>Maximum infusion rate, ml/kg/h</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean</td>
<td>3.9</td>
<td>0.55</td>
<td>3.98</td>
</tr>
<tr>
<td>SD</td>
<td>1.0</td>
<td>0.18</td>
<td>1.81</td>
</tr>
<tr>
<td>Median</td>
<td>4.0</td>
<td>0.50</td>
<td>4.00</td>
</tr>
<tr>
<td>Min</td>
<td>2.0</td>
<td>0.35</td>
<td>0.80</td>
</tr>
<tr>
<td>Max</td>
<td>6.1</td>
<td>1.04</td>
<td>8.00</td>
</tr>
</tbody>
</table>

**Table 3. AEs related to study drug**

<table>
<thead>
<tr>
<th>Related AEs</th>
<th>Frequency of occurrence</th>
<th>Subjects, n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>11</td>
<td>8</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Increase in body temperature</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Hypertension</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Insomnia</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Nausea</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Phlebitis</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Pain in extremity</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Infusion site pain, rash, dermatitis, urticaria, flushing, back pain, burning sensations, anxiety, rhinorrhea</td>
<td>1 each</td>
<td>1 each</td>
</tr>
</tbody>
</table>

**Discussion**

Following the first report on the transient increase of platelet counts in patients with ITP after IGIV [26], IGIV has been widely used in the treatment of this disease. Taking into account the different modes of dosing in clinical practice in recent years, it was decided that a total dose of 2 g/kg given over 2–5 days was to be administered during this study. Of the 23 subjects treated, the majority received the study product over a 2-day period.
The rate of treatment responders in the study (71.4%) is in agreement with data reported in the literature. In a similar study in adults with chronic ITP, treatment response defined as platelet increase to $\geq 50 \times 10^9/l$ was achieved in 73.4% of the subjects [35]. A platelet increase to $\geq 50 \times 10^9/l$ was attained in 75% of the subjects who received a nanofiltered preparation as reported in a study comparing 2 different IGIV preparations [36]. In a study comparing two 12% immunoglobulin preparations, a platelet increase to $\geq 50 \times 10^9/l$ was seen in 75 and 71% of the subjects [37]. The total dose of IGIV administered in these studies was the same we used in our study. A response rate of 75% was also reported in a study on adult ITP patients, some of whom were concurrently on corticosteroids [38]. Response to treatment in that study was defined as platelet increase by $\geq 30 \times 10^9/l$. Platelet response rates vary from study to study and can range from 66.7 to 100% [36, 39]. Eleven subjects in the current study achieved an increase to $\geq 100 \times 10^9/l$, and 8 reached a platelet count of $\geq 200 \times 10^9/l$ over the course of the study. The highest median platelet count in treatment responders was $182 \times 10^9/l$ observed on day 8. The median platelet count in treatment responders on day 5 after the start of the IGIV 10% treatment course was $163 \times 10^9/l$. In a similar study, 1 week after the initiation of treatment, the mean maximum platelet count for responders was $163 \times 10^9/l$ [38]. Starting with mean platelet counts of $30 \times 10^9/l$, a mean platelet increment of $89 \times 10^9/l$ was observed in the treatment responders of another study after a 2-day schedule (1 g/kg/day) of IGIV [40].

Booster treatment of non-responders was not effective in our study. It has been reported in previous studies that, in subjects that did not initially demonstrate an adequate response, a continuation of IGIV treatment made little difference to the platelet count [38]. In the current study, 9 of 23 subjects had been splenectomized prior to study entry. Four of 9 subjects who had previously been splenectomized presented with an extremely low platelet count ($\leq 7 \times 10^9/l$) at baseline. Two of these were non-responders and probably belong to the group of ITP patients who are generally therapy resistant, i.e. are unresponsive to splenectomy and all treatments they receive or require high-dose or additional therapy [41–43]. The other 2 were responders and received corticosteroid treatment both before and during the study. The platelet response observed in the current study was rapid. The median time to platelet response ($\geq 50 \times 10^9/l$) in at least 50% of the subjects) was estimated as 4 days from the beginning of the first treatment. 14 of 15 treatment responders (93.3%) achieved a platelet count of $\geq 50 \times 10^9/l$ within 4 days of treatment initiation. In a similar study, a median time to platelet response (platelet count $\geq 50 \times 10^9/l$) of 3 days was reported [44]. Mean times to platelet response of 4 and 5 days were observed in a study comparing 2 different IGIV products in patients with chronic ITP [36, 37].

The median duration of platelet response observed in the current study was 25 days for the treatment responders and was defined as the duration from the day the platelet count reached or exceeded $50 \times 10^9/l$ to either the first day of the platelet count falling to $<20 \times 10^9/l$ or the last day with available platelet count data. Other studies using the same dose of IGIV reported durations of platelet response ranging from a mean of 10 days with platelet counts of $>50 \times 10^9/l$ [36] to 25.5 days (median) with platelet counts above the baseline level [44]. A median duration of platelet levels above $50 \times 10^9/l$ of 6 and 10 days was reported for a nanofiltered liquid product and its lyophilized predecessor preparation in a study comparing 2 IGIV preparations [37]. Platelet counts of $>30 \times 10^9/l$ for 26 days were reported by Newland et al. [38], and in a very recent study comparing 2 different IGIV preparations, platelet counts of $\geq 50 \times 10^9/l$ were maintained for at least 7 days or more in 74 and 60% of the subjects, respectively [45].

The data on AEs indicate that treatment with IGIV 10% is well tolerated. A total of 84 AEs were reported in 18 subjects, i.e. 78.3% of all subjects. Only 1 SAE was reported, which was classified by the investigator as unrelated to the use of the study drug. The majority of the non-serious AEs reported were mild. 13 subjects (56.5%) reported 40 (48.2%) non-serious AEs that were considered by the investigators to be related to the use of the study drug. Comparable AE rates after administration of high-dose IGIV to ITP patients have been reported in the literature [37, 38, 44]. The AEs most frequently related to the use of IGIV 10% were headache and pyrexia. The types of AEs considered to be causally related to the use of the study drug in the current study are known from previous experience with IGIV; other studies also reported headache and pyrexia among the most frequently-occurring AEs [37, 44, 45]. 3 of the 23 subjects (13.0%) treated with the study drug tested positive in the direct Coombs' test, but no evidence of drug-induced hemolysis was found. In a study with high-dose IGIV for the treatment of ITP, approximately one third of the patients presented with a positive direct antiglobulin test without evidence of clinically significant hemolysis [45]. The results obtained in this study demonstrate that IGIV 10% is effective in the treatment of adult subjects with chronic ITP and is well tolerated.

**Conflict of Interest Statement**

The study was sponsored by Baxter AG, Vienna, Austria. Authors for whom Baxter, Vienna, Austria, is given as affiliation are employees of the study sponsor.
References


